Apilimod may however be a beneficial treatment option for NSCLC patients that express a functional IL-23R, given that it results in significant decreases in proliferation in the A549 adenocarcinoma cell line which expresses higher levels of the IL-23R than the SK-MES-1 cell line. This evidence concerns the gene IL23R and non-small cell lung carcinoma.